Detalhe da pesquisa
1.
Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
J Infect Dis
; 220(3): 411-419, 2019 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31535143
2.
Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
Lancet Infect Dis
; 23(12): 1383-1394, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37660711